PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug
- 1.2k Downloads
Many promising anticancer molecules are abandoned during the course from bench to bedside due to lack of clear-cut efficiency and/or severe side effects. Vitamin K3 (vitK3) is a synthetic naphthoquinone exhibiting significant in vitro and in vivo anticancer activity against multiple human cancers, and has therapeutic potential when combined with other anticancer molecules. The major mechanism for the anticancer activity of vitK3 is the generation of cytotoxic reactive oxygen species (ROS). We thus reasoned that a rational redox modulation of cancer cells could enhance vitK3 anticancer efficiency.
Cancer cell lines with peroxiredoxin 1 (PRX1) gene transiently or stably knocked-down and corresponding controls were exposed to vitK3 as well as a set of anticancer molecules, including vinblastine, taxol, doxorubicin, daunorubicin, actinomycin D and 5-fluorouracil. Cytotoxic effects and cell death events were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based assay, cell clonogenic assay, measurement of mitochondrial membrane potential and annexin V/propidium iodide double staining. Global ROS accumulation and compartment-specific H2O2 generation were determined respectively by a redox-sensitive chemical probe and H2O2-sensitive sensor HyPer. Oxidation of endogenous antioxidant proteins including TRX1, TRX2 and PRX3 was monitored by redox western blot.
We observed that the PRX1 knockdown in HeLa and A549 cells conferred enhanced sensitivity to vitK3, reducing substantially the necessary doses to kill cancer cells. The same conditions (combination of vitK3 and PRX1 knockdown) caused little cytotoxicity in non-cancerous cells, suggesting a cancer-cell-selective property. Increased ROS accumulation had a crucial role in vitK3-induced cell death in PRX1 knockdown cells. The use of H2O2-specific sensors HyPer revealed that vitK3 lead to immediate accumulation of H2O2 in the cytosol, nucleus, and mitochondrial matrix. PRX1 silencing significantly up-regulated mRNA and protein levels of NRH:quinone oxidoreductase 2, which was partially responsible for vitK3-induced ROS accumulation and consequent cell death.
Our data suggest that PRX1 inactivation could represent an interesting strategy to enhance cancer cell sensitivity to vitK3, providing a potential new therapeutic perspective for this old molecule. Conceptually, a combination of drugs that modulate intracellular redox states and drugs that operate through the generation of ROS could be a new therapeutic strategy for cancer treatment.
KeywordsPeroxiredoxin 1 Vitamin K3 Menadione Reactive oxygen species Redox modulation Drug sensitization
Dulbecco’s modified Eagle’s medium
Mitochondrial membrane potential
NRH:quinone oxidoreductase 2
Quantitative real-time PCR
Reactive oxygen species
Small interfering RNA
siRNA targeting PRX1
Non-targeting pool control siRNA
Tetramethylrhodamine methyl ester
Vitamin K3 (2-methyl-1, 4 naphthoquinone, also known as menadione) is a form of vitamin K that does not participate in the synthesis of coagulation proteins [1, 2]. Rather, vitamin K3 (vitK3) is readily redox cycled, thereby generating reactive oxygen species (ROS) and consuming NADPH. VitK3 exhibits anticancer activity against a variety of human cancer cell lines [3, 4, 5, 6]. The association of vitK3-induced cell death with the cellular depletion of glutathione, NADPH oxidation, the occurrence of macromolecular damage, and the disruption of calcium homeostasis, support the notion that the anticancer activity of vitK3 is linked to oxidative stress [3, 7, 8, 9].
The encouraging results obtained in cell models regarding vitK3 anticancer activity have prompted several in vivo investigations. A clinical phase I study showed that vitK3 is reasonably well-tolerated, and the concentrations that are required for suppressing tumor growth in vitro are clinically achievable [3, 10]. On the basis of the synergistic cytotoxicity between vitK3 and other anticancer drugs such as mitomycin C, vitamin C, or radiation in vitro , clinical trials evaluating the therapeutic effect of these combinations have been carried out. An early study showed that vitK3 potentiates radiation efficiency in patients with buccal carcinoma , but a clinical phase II trial of vitK3 and mitomycin C combination in advanced lung cancer patients and gastrointestinal cancer patients failed to demonstrate benefit [2, 11]. However, a clinical phase I/IIa study of the combination of vitK3 and vitamin C in a group of end stage prostate cancer patients who failed standard therapy showed a strong synergistic effect . Taken together, these mixed results indicate that the cancer types, doses of vitK3 and its combination with other drugs, influence the effectiveness of vitK3 as an adjuvant or co-adjuvant in chemotherapy. Additional studies are clearly warranted to optimize the anticancer therapeutic effect of vitK3 and to minimize its toxic side effects.
ROS generation is considered as a key mechanism of vitK3-induced cell death [2, 13], and ROS-mediated cancer cell killing is receiving increasing attention [14, 15, 16]. However, due to the presence of oxidative stress adaptive mechanisms, the use of ROS-generating agents alone may not be sufficient to efficiently kill cancer cells. Therefore, combinations of ROS-generating agents with compounds capable of abrogating cellular antioxidant defense systems are likely to have an additive or even synergistic effect. This approach might be particularly useful for the treatment of drugs-resistant cancer cells that have become adapted to stress. We thus reasoned that redox modulation of cancer cells through peroxiredoxin 1 (PRX1) knockdown could enhance the anticancer activity of vitK3. Peroxiredoxins constitute a large family of thiol-based peroxidases that reduce peroxides with electrons donated by thioredoxin 1 (TRX1) [17, 18], and PRX1 is the most abundant of the six human peroxiredoxins. Importantly, PRX1 is not only important for cellular peroxide scavenging, but also regulates numerous signaling pathways via direct protein-protein interaction with, for instance, ASK1, GSTpi-JNK, AR, PTEN and c-ABL [19, 20, 21], or by modulating H2O2 signaling . PRX1 is frequently over-expressed in various cancer cells including lung, bladder, liver, thyroid, and breast cancers [22, 23, 24], and its over-expression has been associated with carcinogenesis, metastasis and resistance to radiotherapy or chemotherapy [22, 23, 25]. In the present study, we observed that PRX1 knockdown (transient or stable silencing) enhanced the toxic effect of vitK3 on cancer cells (A549 and HeLa) with little or no effect on non-transformed immortalized cells and primary fibroblasts. This selective cytotoxicity in PRX1 knockdown cancer cells is associated with a significant cellular accumulation of H2O2 partially due to an overexpression of NRH:quinone oxidoreductase 2 (NQO2). PRX1 inactivation could represent an interesting strategy to enhance cancer cell sensitivity to vitK3, providing a potential new therapeutic perspective for this old molecule.
VitK3, N-ethylmaleimide (NEM), N-acetyl-L-cysteine (NAC), dimethyl sulfoxide (DMSO), dithiothreitol (DTT), H2O2 and trichloroacetic acid (TCA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Vinblastine, taxol, doxorubicin, daunorubicin, actinomycin D and 5-fluorouracil were from Enzo Life Sciences (Villeurbanne, France). Hygromycin B, 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), crystal violet, Vybrant Apoptosis Assay Kit #3, propidium iodide (PI), tetramethylrhodamine methyl ester (TMRM), 4-acetamido-4’-maleimidylstilbene-2,2’-disulfonic acid (AMS) were from Life Technologies (Eugene, OR, USA). The following antibodies were used: anti-PRX1 (AbFrontier, Seoul, Korea); anti-PRX3 (Abcam, Cambridge, MA, USA); anti-TRX2 (R&D Systems, Minneapolis, MN, USA); anti-NQO2 (Proteintech, Chicago, IL, USA); anti-GFP (Life Technologies); anti-β-actin (Santa Cruz Biotechnology); anti-α-tubulin (Sigma-Aldrich) and anti-TRX1 (Cell Signaling Technology, Danvers, MA, USA). ON-TARGETplus SMARTpool small interfering RNA (siRNA) targeting PRX1 (siPrx1), and non-targeting pool control siRNA (siCon) were from Dharmacon (Lafayette, CO, USA). Mammalian expression vectors encoding HyPer targeted to cytosol, nucleus and mitochondria were purchased from Evrogen (Moscow, Russia).
Human cervical adenocarcinoma HeLa and human lung cancer A549 cell lines were from American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured in standard Dulbecco’s modified Eagle’s medium (DMEM) with 10 % fetal bovine serum (FBS). Human vascular endothelial cell line HUVEC was from ATCC and cultured in standard DMEM with 10 % FBS. Primary normal dermal fibroblasts from ATCC were kindly provided by Dr. Matthieu Gratia (UMR3348 CNRS-Institut Curie, Orsay, France) and cultured in DMEM with 20 % FBS. The HeLa cells stably knocked-down for PRX1 gene (PRDX1 HeLa SilenciX, designated as Prx1– cells) and non-silenced control cells (Control HeLa SilenciX, designated as Prx1+ cells) were purchased from tebu-bio (Le Perray en Yvelines, France) and were cultured in DMEM supplemented with 50 μg/mL hygromycin B and 10 % FBS. All cell lines have been characterized and the last cell line authentication has been performed by eurofins (Ebersberg, Germany) using PCR-single-locus technology after finalization of the present study.
siRNA and plasmid transfection
For siRNA transfection, HeLa, A549 and HUVEC cells and primary normal dermal fibroblasts were seeded at density of 4 × 103 per well into a 96-well plate or at 1 × 105 per well into a 6-well plate the day before transfection. Cells were then transfected with 5 nM siRNA (for HeLa, A549 and HUVEC cells) or 15 nM siRNA (for primary normal dermal fibroblasts) using INTERFERin reagents (Polyplus Transfection, Illkirch, France) according to the manufacturer’s instructions. Further experiments were performed 48 h after transfection. For HyPer transfection, HeLa cells were seeded at density of 4 × 105 per well into a 6-well plate the day before transfection and were then transfected with 1 μg of HyPer expressing vectors using jetPRIME reagents (Polyplus Transfection).
Cell viability and cell death assays
MTT-based cell viability assay was performed as previously reported . For cell clonogenic assay, ~300 cells per well were plated in 6-well plates and cultured at 37 °C overnight. Cells were then treated with indicated doses of vitK3 or DMSO (as vehicle control) for defined times followed by incubation in fresh medium for another 10 days. The culture medium was changed with fresh medium every 3 days. The cells were then fixed and stained with 0.05 % crystal violet in 70 % ethanol. The number of visible colonies was counted manually. Mitochondrial membrane potential (MMP) was monitored by TMRM staining, for which cells were washed with PBS and incubated with 10 nM TMRM for 30 min at 37 °C before being analyzed by flow cytometry. Fluorescent isothiocyanate (FITC)-conjugated annexin V/PI double staining was performed using the Vybrant Apoptosis Assay Kit #3 according to the manufacturer’s instructions. Cells were analyzed in FL1-H (FITC) and FL2-H (PI) channels on flow cytometer equipped with CellQuest software (FACSCalibur, Becton Dickinson).
Measurement of ROS
The general intracellular ROS was assessed using carboxy-H2DCFDA. Briefly, cells were trypsinized, resuspended in medium without phenol red and serum, and stained with 10 μM carboxy-H2DCFDA for 30 min at 37 °C in the dark. The cells were then washed in PBS, collected and analyzed immediately by flow cytometry.
Real-time imaging of the H2O2 dynamics was monitored with the genetically encoded fluorescent probe HyPer . Fluorescent imaging in living cells was performed using the microscope Leica DMI6000 B equipped with Leica MM AF Imaging System. Images were acquired using excitation filters YFPex (490–510 nm) and CFPex (420–445 nm) and emission filter YFPem. Time-lapse imaging was recorded every 10 s with Plan Fluotar dry objective (magnification 40×, numerical aperture 0.6). Images were then subtracted from background and filtered with median method in ImageJ software (National Institutes of Health, Bethesda, MD, USA). Ratio from average fluorescence intensity of channel YFPex/YFPem (F) divided by that of channel CFPex/YFPem (F0) was calculated frame by frame, followed by normalization to the value of images at start point of vitK3 treatment.
Western blotting and redox western blotting
For classic western blotting, cells were lysed in M-PER protein extraction reagent (Pierce, Rockford, IL, USA) supplemented with 0.5 mM DTT and complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Lysates were resolved by 4–12 % (for PAR detection) or 12 % NuPAGE Bis-Tris gel (for other proteins) with MOPS buffer (Life Technologies) under reducing condition. Redox western blotting method was previously described . Briefly, cells in culture were acid-quenched with ice-cold 10 % TCA, harvested, washed with acetone and dissolved in lysis buffer (100 mM Tris-Cl, 1 % SDS, 10 mM EDTA, pH 8.8) supplemented with 30 mM AMS (for TRX1 and TRX2) or 25 mM NEM (for PRX3 and HyPer). Following 2 h incubation under shaking at 37 °C (for AMS-treated samples) or 30 °C (for NEM-treated samples), insoluble protein was removed by centrifugation. Each sample containing about 30 μg of protein was separated by 4–12 % Bis-Tris gel with MOPS buffer (for HyPer) or 12 % Bis-Tris gel with MES buffer (for TRX1, TRX2 and PRX3, Life Technologies) under non-reducing condition. For both classic and redox western blotting, blots after incubation with first antibodies were washed and probed with IRDye 680- or IRDye 800cw-conjugated secondary antibody (LI-COR Biosciences, Lincoln, NE, USA) and then analyzed using an Odyssey Infrared Imaging System (LI-COR). Scanned images and band integrated intensity were analyzed and quantified by Odyssey v3.0 software.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated with RNeasy Protect Mini Kit (Qiagen GmbH, Hilden, Germany). cDNA was generated using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Forward and reverse primers for GAPDH and NQO2 genes were synthesized according to the sequence previously described [28, 29]. GAPDH served as a reference gene for relative quantification. qRT-PCR was performed with iQ SYBR Green Supermix (Bio-Rad) in a CFX96 real-time PCR detection system (Bio-Rad).
All the values are the means ± SD of not less than three measurements except indicated. Comparisons between groups were analyzed using Student’s t-test. P values of ≤0.05 were considered significant.
PRX1 knockdown confers selective sensitivity to vitk3 in cancer cell lines
In order to decipher the mechanisms underlying cancer-cell-selective cytotoxicity of vitK3 in PRX1-silenced cancer cells, we decided to use a cancer cell model where PRX1 was stably knockdown. To this end, we employed commercially available HeLa (Prx1–) and the corresponding control (Prx1+) cell lines. The efficiency of PRX1 knockdown was previously confirmed by qRT-PCR and western blot . Based on the MTT assay, Prx1– cells exhibited a significant and highly reproducible hypersensitivity to vitK3. Similar to transient knockdown experiments, 4 h treatment with 15 μM vitK3 killed ~80 % of Prx1– cells while Prx1+ cells were not or only barely affected; after a 24 h treatment, ~90 % of Prx1– cells were dead, versus ~40 % for Prx1+ cells (Fig. 1e). Clonogenic assay further confirmed the enhanced vitK3 cytotoxicity in Prx1– cells. The clonogenic ratio of Prx1– cells was <5 % versus ~50 % for Prx1+ cells upon exposure to 15 μM vitK3 for 4 h (Fig. 1f).
The enhanced sensitivity to vitK3 involves possibly necroptosis
A major accumulation of H2O2 underlies Prx1– cells sensitivity to vitK3
We next investigated the effect of the H2O2 produced upon vitK3 treatment on the expression and redox states of the cytosolic (TRX1) and mitochondrial (TRX2) thioredoxins and of PRX3 which is a peroxiredoxin located in the mitochondrial matrix and a major H2O2-scavenging enzyme within this compartment [37, 38]. As shown in Fig. 5b, TRX1 and TRX2 were mostly in the reduced form in both Prx1+ and Prx1– cells, TRX1 remained reduced upon addition of vitK3 while TRX2 became oxidized up to 50 % in Prx1– cells. On the other hand, TRX1 and TRX2 protein levels, which were initially elevated in Prx1– cells compared with Prx1+ cells, decreased by 2–3 fold upon drug treatment whereas they remained constant in Prx1+ cells (Fig. 5b). PRX3 levels were not different between Prx1– and Prx1+ cells; however the enzyme underwent rapid oxidation upon drug treatment, as manifested by the apparition of characteristic disulfide-linked dimers, and this oxidation was more pronounced in Prx1– cells (Fig. 5c). In summary, vitK3 treatment leads to pronounced redox alterations in Prx1– cells, including H2O2 accumulation, TRX2 and PRX3 oxidation, and a decrease in the protein levels of both TRX1 and TRX2. All may contribute to an enhanced vitK3 cytotoxicity.
To assess the causative role of ROS in vitK3-induced cell death, we tested the effect of the antioxidant NAC on cell survival. The addition of 10 mM NAC nearly completely prevented vitK3-induced death of Prx1– cells (Fig. 5d). NAC also prevented the accumulation of ROS and more specifically H2O2 after vitK3 treatment, as revealed by carboxy-H2DCFDA fluorescence and by the redox state of HyPer probes (Fig. 5e). These data strongly suggest that the increased ROS accumulation in Prx1– cells has a causative role in vitK3-induced cell death.
Enhanced sensitivity to vitK3 in Prx1– cells relies on NQO2 expression
Rational drug combinations directed against multiple targets are effective anticancer strategies, by preventing cancer drug resistance and allowing the use of lower therapeutic drug posologies, thus overcoming the side effects of high doses of the single drugs. In the present study, we showed that PRX1 knockdown significantly and specifically potentiates vitK3 cellular sensitivity, which allows the reduction of the doses necessary to kill cancer cells. MTT and clonogenic assays, TMRM and annexin V/PI double staining all demonstrated that a 24 h treatment with 15 μM vitK3 is enough to trigger cell death and kill a significant proportion of PRX1 knockdown cancer cells. Importantly, such treatments caused little apparent reduction in cell viability of non-cancerous cells, with or without PRX1 knockdown. This indicates that vitK3 has a cancer-cell-selective cytotoxic property, in particular when PRX1 activity is compromised.
Using recently developed redox analysis tools, we demonstrated that 15 μM vitK3 triggered a rapid and significant accumulation of H2O2 in the mitochondrial matrix, cytosol and nucleus in Prx1– cells. This ROS accumulation of H2O2 played a determinant role in enhanced vitK3-induced cell death. Up-regulation of NQO2 in Prx1– cells appears to contribute to the increased H2O2 generation in the presence of vitK3. How PRX1 knockdown leads to the up-regulation of NQO2 remains unknown. NQO2 gene contains the antioxidant response element (ARE) in its promotor region and is part of the Nrf2-regulated defensive mechanism . It is possible that PRX1 knockdown causes redox imbalance that up-regulates the expression of some Nrf2-regulated ARE-containing genes including NQO2. NQO2 catalyzes metabolic activation of vitK3 leading to cytotoxicity, in contrast to NADPH:quinone oxidoreductase (NQO1) that metabolically detoxifies vitK3 and protects cells against oxidative stress . As 15 μM vitK3 induced only minor ROS accumulation and cytotoxicity in Prx1+ cells, we propose that the rapid and important ROS elevation in Prx1– cells could be derived from a combined effect of an increased H2O2 generation during vitK3 metabolism by higher NQO2 activity and a decreased PRX1 scavenging activity. Enhanced H2O2 accumulation in Prx1– cells upon vitK3 treatment is detected in the three subcellular compartments analyzed with a marked effect on mitochondrion. This was confirmed by the oxidation of TRX2 and PRX3, two major mitochondrial redox-maintaining-antioxidant proteins , which may reflect a widespread mitochondrial protein oxidation and is likely to further facilitate H2O2 accumulation in mitochondria, leading eventually to cell death.
VitK3 and β-lapachone (β-lap) both trigger remarkable accumulation of H2O2 in PRX1 knockdown HeLa cells . However, although these two quinones are supposed to share similar redox cycling pathways, they implicate different mechanisms. ROS accumulation in vitK3-treated and β-lap-treated Prx1– cells depends on NQO2 and NQO1, respectively. In particular, NQO1 catalyzes a two-electron reduction of both vitK3 and β-lap . While vitK3 is detoxified by NQO1 , β-lap toxicity is strongly potentiated by this enzyme activity . On the other hand, inhibition of NQO2 (present study) or the absence of NQO2 (NQO2-null mice) confers resistance to vitK3-induced oxidative stress and cytotoxicity . The role of NQO2 in β-lap toxicity remains unknown. Nonetheless, we observed that quercetin, a NQO2 inhibitor, significantly attenuated β-lap-induced cell death (data not shown), indicating the enhancing role of NQO2 in both β-lap and vitK3 cytotoxicity. In addition to distinct metabolisms related to ROS generation, the downstream events and signaling pathways that lead to cell death in response to β-lap and to vitK3 seems to be different. Among the MAPK pathways analyzed, JNK, p38 and ERK are highly phosphorylated after β-lap treatment and JNK activation plays a critical role in mediating low-dose β-lap-induced cell death in Prx1– cells . However, an equivalent lethal dose of vitK3 results in moderate ERK phosphorylation that does not influence vitK3-induced Prx1– cell death (data not shown). It will be interesting to identify the distinct mechanisms of action of these two related quinone molecules, linking ROS accumulation and downstream signaling pathways.
VitK3-induced cancer-cell-selective toxicity is consistent with the notion that cancer cells usually display persistent pro-oxidative state. As such, cancer cells would be more dependent on the antioxidant system to maintain the ROS levels below the toxic threshold, and therefore more vulnerable to further oxidative stress induced by exogenous ROS-generating agents or by defective antioxidant system. Our current findings further support the view that modulation of intracellular redox states is a viable alternative approach to enhance cancer cell sensitivity to ROS-generating drugs, or to overcome some types of drug resistance [14, 15]. Elevated expression of PRX1 has frequently been found in various cancer cells [22, 24] and PRX1 is responsible for cell resistance to TRAIL and cisplatin [25, 46]. Therefore, PRX1 is an interesting target in an oxidative stress-modulating anticancer strategy. From this study, it is reasonable to expect a reduction of ~40 to ~50 % of vitK3 doses when administrated with an efficient PRX1 inhibitor, with better anti-cancer efficiency and less side effects. As no specific PRX1 inhibitor is currently commercially available, the reported peroxiredoxin inhibitors such as Conoidin A and Adenanthin inhibit preferentially peroxiredoxin 2 and affect other antioxidant pathways [47, 48, 49], the use of such inhibitors is less appealing for the establishment of a PRX1-based redox anticancer therapeutic strategy. Our data obtained by specific PRX1 knockdown approach provide a proof of concept that PRX1 could be an interesting anticancer target leading to a substantial reduction of the vitamin K3 dosage to kill cancer cells. The development of new specific and efficient PRX1 inhibitors could open new avenues for redox-based anticancer therapies.
Killing cancer cells by a ROS-mediated mechanism has received increasing attention recently. However, due to the presence of redox adaptation mechanisms, the use of ROS-generating agents alone may not be sufficient to efficiently kill cancer cells exhibiting up-regulated antioxidants. Redox modulation of cancer cells by PRX1 knockdown confers enhanced sensitivity to vitK3 through increased ROS accumulation. PRX1 could be an anticancer target leading to a substantial reduction of the vitK3 dosage to kill cancer cells. Conceptually, a combination of drugs that modulate intracellular redox states and drugs that operate through the generation of ROS could be a new therapeutic strategy for cancer treatment.
We thank Roland Chanet, Michèle Dardalhon, Amélie Masurel-Heneman, Dorothée Baille, Guy Kienda, Gérard Faye and Michel B. Toledano for helpful discussions, Michel B. Toledano and Weiwei Huang for critical reading of the manuscript. We also thank Matthieu Gratia for primary normal dermal fibroblasts, Institut Curie imaging facility and Daniel Zaharia for technical assistance to fluorescence microscopic analysis. This work was supported by the Centre National de la Recherche Scientifique (CNRS), the Institut Curie, and the Comité de l’Essonne de la Ligue Nationale Contre le Cancer (to M.-E. Huang). Titantian He is supported by a PhD fellowship from the China Scholarship Council. Elie Hatem is supported by a postdoctoral fellowship from the Ligue Nationale Contre le Cancer.
- 1.Gong X, Gutala R, Jaiswal AK. Quinone oxidoreductases and vitamin K metabolism. In: Gerald L, editor. Vitamins and Hormones, Academic Press; 2008. 85–101.Google Scholar
- 5.Suresh S, Raghu D, Karunagaran D. Menadione (Vitamin K3) induces apoptosis of human oral cancer cells and reduces their metastatic potential by modulating the expression of epithelial to mesenchymal transition markers and inhibiting migration. Asian Pac J Cancer Prev. 2013;14:5461–5.PubMedCrossRefGoogle Scholar
- 30.Skeel RT. Handbook of Cancer Chemotherapy. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.